Exubera® (inhaled insulin): An evidence-based review of its effectiveness in the management of diabetes

Core Evidence

Volumn 1, Issue 2, 2005, Pages 89-101

  Profit, Louise ^a  

^a Core Medical Publishing ^*  (United Kingdom)

Author keywords

Evidence; Glycemic control; Inhaled insulin; Outcomes; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ACARBOSE; AERODOSE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; INSULIN ANTIBODY; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; TOLAZAMIDE;

ASTHMA; CIGARETTE SMOKING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG FUNCTION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PREVALENCE; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 33646481240     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. AACE (American Association of Clinical Endocrinologists). State of Diabetes in America. Available at: http://www.stateofdiabetes.com (accessed June 23, 2005).
2. ADA (American Diabetes Association). Insulin administration. Diabetes Care. 2004;27(Suppl. 1):S106-S109.
3. ADA (American Diabetes Association). National Diabetes Fact Sheet, 2005a. Available at: http://www.diabetes.org/diabetes-statistics/national-diabetes- fact-sheet.jsp (accessed May 5, 2005).
4. ADA (American Diabetes Association). Resource Guide 2005. Diabetes Forecast. 2005b;58(1).
5. ADA (American Diabetes Association). Standards of medical care in diabetes. Diabetes Care. 2005c;28(Suppl. 1):S4-S36.
6. Barlocco D. LAF-237 (Novartis). Curr Opin Invest Drugs. 2004;5:1094-1100.
7. Barnett AH, for the Exubera Phase III Study Group. Efficacy and one-year pulmonary safety of inhaled insulin (Exubera) as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled on oral agent monotherapy. Diabetes. 2004;53(Suppl. 2):A107.
8. Becker RHA, Sha S, Frick AD, Piechatzek R. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin (Exubera®). Diabetes. 2003;52(Suppl. 1):A37.
9. Belmin J, Valensi P. Novel drug delivery systems for insulin: clinical potential for use in the elderly. Drugs Aging. 2003;20(4):303-312.
10. Bergenstal R, for the Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera®) compared with rosiglitazone in type 2 diabetes patients not optimally controlled on diet and exercise: results of a 3-month, randomized, comparative trial. Diabetologia. 2003;46(Suppl. 2):A277.
11. 1c in studies with inhaled insulin in type 2 diabetes. Diabetologia. 2004;47(Suppl. 1):A312.
12. Cappelleri JC, Gerber RA, Kourides IA, Gelfand RA. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. Diabetes Care. 2000;23(12):1799-1803.
13. Cappelleri JC, Gerber RA, Rosenstock J, et al. Relationship between improved patient satisfaction and improved glycemic control in patients with type 1 and type 2 diabetes mellitus treated with inhaled insulin. Diabetes. 2001;50(Suppl. 2).
14. Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther. 2002;24(4):552-564.
15. CDC (Centers for Disease Control and Prevention). National Diabetes Fact Sheet, USA, 2003. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2003. pdf (accessed January 21, 2005).
16. Cefalu WT. Inhaled insulin: A proof-of-concept study. Ann Intern Med. 2001;134(9 Part 1):795.
17. Cefalu WT, for the Exubera Phase 3 Study Group. Mealtime rapid-acting inhaled insulin (Exubera) improves glycaemic control in patients with type 2 diabetes failing combination oral agents: A 3-month, randomised, comparative trial. Diabetologia. 2002;45:A260.
18. Cefalu WT. Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care. 2004;27(1):239-246.
19. Cefalu WT, Serdarevic-Pehar M, for the Exubera Phase 3 Study Group. Long-term use of Exubera in type 2 diabetes: observations on glycemic control, pulmonary function and antibody formation. Diabetes. 2005;54(Suppl. 1):Abstract 356-OR.
20. Clarke P, Gray A, Adler A, et al.; UKPDS Group. United Kingdom Prospective Diabetes Study. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia. 2001;44(3):298-304.
21. Cramer JA, Okikawa J, Bellaire S, Clauson P. Compliance with inhaled insulin treatment using the AERx Idms Insulin Diabetes Management System. Diabetes Technol Ther. 2004;6:800-807.
22. DCCT (Diabetes Control and Complications Trial) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
23. DeFronzo R. Efficacy and safety of inhaled insulin (Exubera®) compared with rosiglitazone in type 2 diabetes patients not optimally controlled on diet and exercise: Results of a 3-month, randomized, comparative trial. Diabetes. 2003;52(Suppl. 1):A38 (Abstract 162).
24. Dreyer M. Efficacy and two-year pulmonary safety of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled with oral monotherapy. Diabetologia. 2004;47(Suppl. 1):A44.
25. Dumas R, Krasner AS, England RD, Riese RJ, Teeter JG, for the Exubera Phase 3 Study Group. Exubera is well tolerated and achieves tight glycemic control in patients with type 1 diabetes. Diabetes. 2005a;54(Suppl. 1):Abstract 355-OR.
26. Dumas R, Krasner AS, England RD, Riese RJ, Teeter JG, for the Exubera Phase 3 Study Group. Immunologic response to Exubera in patients with type 1 diabetes is not associated with functional evidence of airway sensitization. Diabetes. 2005b;54(Suppl. 1):Abstract 437-P.
27. EDPG (European Diabetes Policy Group) (International Diabetes Federation European Region). A desktop guide to type 2 diabetes. Diabetic Med. 1999;16:716-730.
28. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab. 2005;90:3287-3294.
29. Freemantle N, Blonde L, Duhot D et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care. 2005;28:427-428.
30. Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care. 2001;24(9):1556-1559.
31. Gilmer TP, O'Connor PJ, Manning WG, et al. The cost to health plans of poor glycemic control. Diabetes Care. 1997;20:1847-1853.
32. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ. 2000;320(7246):1373-1378.
33. Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study. Diabetes Metab Res Rev. 2004a;20(6):472-478.
34. Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents. Diabetes Technol Ther. 2004b;6(1):1-8.
35. Heise T, Tusek C, Stephan J-A, et al. Postprandial glucose control unaffected by insulin antibodies associated with inhaled insulin. Diabetologia. 2004a;47(Suppl. 1):A311.
36. Heise T, Tusek C, Stephan J-A, et al. Insulin antibodies with inhaled insulin (Exubera): no evidence for impact on postprandial glucose control. Diabetes. 2004b;53(Suppl. 2):A109.
37. Henry RR, Mudaliar SR, Howland WC 3rd, et al. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care. 2003a;26(3):764-769.
38. Henry RR, Mudaliar S, Chu N, et al. Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J Clin Pharmacol. 2003b;43(11):1228-1234.
39. Henry RR, Mudalier SR, Fryburg DA, et al. Within-subject variability of inhaled insulin (Exubera®) versus subcutaneous regular insulin in elderly obese patients with type 2 diabetes mellitus. Diabetes. 2003c;52(Suppl. 1):A105.
40. Himmelmann A, Jendle J, Mellen A, Petersen AH, Dahl UL, Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care. 2003;26(3):677-682.
41. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-932.
42. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;Oct;27(10):2356-2362.
43. IDF (International Diabetes Federation). Diabetes Facts & Figures. Available at: http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3- 87B73F80BC226 (accessed January 19, 2005).
44. Jones JG, Minty BD, Lawler P, Hulands G, Crawley JC, Veall N. Increased alveolar epithelial permeability in cigarette smokers. Lancet. 1980;1(8159):66-68.
45. Jonsson B; CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002;45(7):S5-12.
46. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27(1):17-20.
47. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(Suppl. 3):S18-24.
48. Krentz AJ, Bailey CJ. Oral antidiabetic agents. Current role in type 2 diabetes mellitus. Drugs. 2005;65:385-411.
49. Mandal TK. Inhaled insulin for diabetes mellitus. Am J Health-Syst Pharm. 2005;62:1359-1364.
50. NICE (National Institute for Health and Clinical Excellence). Clinical guidelines for type 2 diabetes: Management of blood glucose. September 2002. Available at: http://www.nice.org.uk (accessed February 28, 2005).
51. Nielsen LL. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today. 2005;10(10):703-710.
52. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
53. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabetic Med. 2003;20:886-898.
54. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet. 2004;43(12):781-801.
55. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693-700.
56. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL; Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27(11):2622-2627.
57. Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care. 2005;28:1077-1082.
58. Rosenstock J, for the Exubera Phase III Study Group. Mealtime rapid-acting inhaled insulin (Exubera) improves glycemic control in patients with type 2 diabetes failing combination oral agents: a 3-month, randomized, comparative trial. Diabetes. 2002;51(Suppl. 2):A132.
59. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care. 2004;27(6):1318-1323.
60. Royle P, Waugh N, McAuley L, McIntyre L, Thomas S. Inhaled insulin in diabetes mellitus. Art. No.:CD003890.pub2. DOI: 10.1002/14651858.CD003890.pub2. Cochrane Database of Systematic Reviews. 2003, Issue 4.
61. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421-431.
62. Sha S, Becker RHA, Willavize SA, et al. The effect of smoking cessation on the absorption of inhaled insulin (Exubera®). Diabetes. 2002;51(Suppl. 2):A133.
63. Simonson DC, Hayes JF, Turner RR, Testa MA. Treatment satisfaction and preferences in type 2 diabetes: A randomized trial of oral agents vs. inhaled insulin. Diabetes. 2001;50(Suppl. 2):A131.
64. Simonson DC, Turner RR, Hayes JF, Scranton RE, Testa MA. Improving quality of life in type 2 diabetes when Exubera is added after failure on metformin: a multicenter, international trial. Diabetologia. 2004;47(Suppl. 1):A311.
65. Skyler JS, Cefalu WT, Kourides IA et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: A randomized proof-of-concept study. Lancet. 2001;357:331-335.
66. Skyler JS. Long-term, sustained efficacy, and safety of inhaled insulin after 4 years of continuous therapy. Diabetologia. 2004a;47(Suppl. 1):A311.
67. Skyler J, for the Exubera Phase II study group. Sustained long-term efficacy and safety of inhaled insulin during 4 years of continuous therapy. Diabetes. 2004b;53(Suppl. 2):A115.
68. Skyler JS, Weinstock RS, Raskin P, et al. Use of inhaled insulin in a basal/bolus insulin regimen in subjects with type 1 diabetes: A 6-month, randomized, comparative trial. Diabetes Care. 2005;28:1630-1635.
69. Steiner S, Pfutzner A, Wilson BR, et al. Technosphere/insulin-proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes. 2002;110:17-21.
70. Su M, Testa MA, Turner RR, et al. The relationship between regimen burden and psychological well-being in persons with type 1 diabetes: inhaled vs injectable insulin. Diabetes. 2002;51(Suppl. 2):A448-A449.
71. Testa MA, Turner RR, Hayes JF, et al. Patient satisfaction and quality of life in type 1 diabetes: A randomized trial of injectable vs. inhaled insulin. Diabetes. 2001a;50(Suppl. 2):A45.
72. Testa MA, Turner RR, Hayes JF, et al. Intensive therapy and patient satisfaction in type 1 diabetes: A randomized trial of injected vs inhaled insulin. Diabetologia. 2001b;44(Suppl. 1):A4.
73. Testa MA, Turner RR, Hayes JF, et al. Patient satisfaction with insulin therapy in type 2 diabetes: A randomized trial of injectable vs inhaled insulin. Diabetes. 2002;51(Suppl. 2):A135.
74. Testa MA, Turner RR, Hayes JF, Scranton RE, Simonsen DC. An international trial of sulfonylurea plus either metformin or Exubera: impact on quality of life and treatment satisfaction. Diabetologia. 2004a;47(Suppl. 1):A5.
75. Testa MA, Hayes JF, Turner RR, Simonsen DC. Satisfaction and quality of life with sulfonylurea plus either metformin or Exubera: An international randomized Phase 3 trial. Diabetes. 2004b;53(Suppl. 2):A115.
76. Testa MA, Hayes JF, Turner RR, Simonsen DC. Quality of life improvements in type 2 diabetes when Exubera is added after failure on metformin monotherapy: An international randomized Phase 3 trial. Diabetes. 2004c;53(Suppl. 2):A437.
77. UKPDS (UK Prospective Diabetes Study) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998a;352:854-865.
78. UKPDS (UK Prospective Diabetes Study) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998b;352:837-853.
79. Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Landschulz WH; Inhaled Insulin Phase II Study Group. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med. 2003;163:2277-2282.